IMAGE: The diagram shows the use of the new inhibitor for the treatment of triple-negative breast cancer. view more
Chemists at Hong Kong Baptist University (HKBU) have discovered the use of a metal compound that inhibits the enzyme closely associated with triple-negative breast cancer (TNBC), one of the most difficult forms of breast cancer to treat. The metal compound is found to inhibit the TNBC tumours with less toxicity in mice, thus their work has further unmasked the role of the enzyme, lysine-specific demythylase 5A (KDM5A), in TNBC. The reported compound shows tremendous potential for the development of drugs for TNBC therapy. The results of this study were published in the leading chemistry journal Angewandte Chemie International Edition.
The team was led by Dr Edmond Ma Dik-lung, Associate Professor of HKBU’s Department of Chemistry. The team developed the compound using a metal named rhodium as a direct, potent and selective inhibitor of KDM5A, in other words the compound can effectively target KDM5A which is a key limitation of existing KDM5A inhibitors.
Dr Edmond Ma said that KDM5A is overexpressed in breast cancer and other human cancers, including brain, lung and gastric cancers, thus promoting carcinogenesis and drug resistance. Up to
Article originally posted at